Precision oncology depends on biomarker testing to uncover the molecular drivers of cancer. However, no single assay captures the full picture of tumor complexity. Tissue and liquid biopsy each offer distinct, complementary windows into solid tumor analysis, and combining them delivers a more comprehensive molecular view to guide decision-making.

This webinar will examine how tissue and liquid biopsy data can be unified within a decentralized workflow using the SOPHiA DDM™ Platform in combination with end-to-end Memorial Sloan Kettering Cancer Center (MSK) solutions, enabling comprehensive genomic profiling without compromising data locality or turnaround time.

Key topics will include:

• The rationale for combining tissue and liquid biopsy analysis to strengthen oncology research, including how each modality addresses the limitations of the other.
• Real-world implementation of comprehensive genomic profiling solutions at Tata Memorial Hospital, India, illustrating tissue and liquid biopsy workflows in practice.
• Recent enhancements to MSK powered with SOPHiA DDM™ solutions, expanding capabilities for advanced solid tumor analysis, including tumor content estimates and broader biomarker detection.

Speakers

• Dr. Omshree Shetty, Ph.D., Scientific Officer, Assistant Professor, Molecular Pathology Laboratory, Tata Memorial Hospital
• Lina Li, Director of Product Marketing for Solid Tumors, SOPHiA GENETICS

BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

• Revenue was $24.3 million, up 25% year-over-year on a reported basis
• Gross margin was 65.7% on a reported basis and 72.8% on an adjusted basis, compared to 66.3% reported and 73.1% adjusted in the prior year period
• Net loss was $20.3 million, up 1% year-over-year; Adjusted EBITDA loss was $6.1 million, improving 31% year-over-year
• The company now expects full-year 2026 revenue to be at the upper end of its previously issued guidance range of $94 million to $96 million, reflecting strong business performance partially offset by the impact of foreign exchange rate movements at the end of the third quarter, which, if sustained, would be a headwind to fourth-quarter revenue.

“Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year,” said Ross Muken, Chief Executive Officer of SOPHiA GENETICS. “We also meaningfully improved adjusted EBITDA by 31%, bringing us closer to profitability and further demonstrating the highly scalable nature of our AI-native platform and business model.”

“Looking ahead, new geographies, exciting new products, and expanded relationships with BioPharma offer meaningful catalysts for future growth. We signed 30 new genomics customers in Q3 and closed three material BioPharma deals, including two companion diagnostic programs and a new, multimodal AI project announced today. These partnerships position us well for 2027 and further extend the reach of our clinical intelligence to more patients worldwide.” 

Business Highlights

Expanding with existing customers

• Performed a record 118,000 analyses on SOPHiA DDM^TM, representing 19% year-over-year volume growth
• Delivered strong growth in North America (NORAM) and Asia Pacific (APAC) with 45% and 33% year-over-year revenue growth, respectively
• Expanded our footprint with existing customers as Net Dollar Retention increased to 118% in Q3 2026, up from 108% in Q3 2025
• Reached 551 core genomics customers as of September 30, 2026, up from 488 customers in the prior year period

Landing new customers to fuel future growth

• Signed 30 new core genomic customers in Q3 2026, which are expected to begin generating revenue over the next twelve months
• Continued to sign premier healthcare institutions across the globe, including University of Newcastle, a globally renowned research university in Australia, for Rare Disorders; King Chulalongkorn Memorial Hospital, one of the most prestigious academic medical centers in Thailand, for Solid Tumors and HemOnc; and HBIOMOL, an established diagnostics network in Brazil, for Rare Disorders

Accelerating growth in the U.S. market

• Achieved 41% year-over-year revenue growth in the U.S. in Q3 2026
• Signed two new customers in the U.S., including PathGroup, one of the largest physician-led pathology and clinical laboratory service providers in the U.S., for Solid Tumors and HemOnc, and the University of Arkansas for Medical Sciences (UAMS), Arkansas’s only health sciences university and largest public employer, for HemOnc; these accounts are expected to ramp up in 2027
• Expanded our long-standing partnership with the Molecular Diagnostics Laboratory at the University of North Carolina (UNC) Medical Center to adopt HemOnc, Hereditary Cancer, and Rare Disorders applications, in addition to applications they currently run today
• Signed a notable expansion deal with a leading U.S. military medical center, valued at over $2 million per year, for Rare Disorders applications

Scaling growth with new applications

• Performed 4,200 Liquid Biopsy analyses in Q3 2026, up 100%+ year-over-year, as more customers continue to implement the application and ramp usage
• Signed major new customers to MSK-ACCESS^® powered with SOPHiA DDM^TM in Q3, including University Hospital Augsburg, one of the largest university hospitals in Germany; Agilus Diagnostics, one of the largest diagnostic laboratory networks in India; and Hanusch Krankenhaus, a leading hospital in Austria
• Signed major new customers to the Solid Tumor application MSK-IMPACT^® powered with SOPHiA DDM^TM, including AOU Pisana, a leading university hospital in Italy; Géntodos, an emerging genomics company in Mexico; and Ruhr University Bochum, a large academic pathology institute in Germany

Building BioPharma partnerships

• Signed a new multimodal AI collaboration with a top BioPharma company to develop a multimodal AI predictor to help identify which bladder cancer patients are most likely to benefit from a targeted therapy
• Signed a multi-year agreement with AstraZeneca in Q3 to launch two companion diagnostic (CDx) programs: (1) a decentralized Solid Tumor CDx, and (2) a Hematological Oncology test for patients with blood cancer
• Announced additional details on the Solid Tumor CDx, including the incorporation of Myriad Genetics’ novel prostate cancer-specific genomic instability score (PrGIS) technology into the Extended Homologous Recombinant Solution (HRS), powered by SOPHiA DDM^TM
• Delivered strong growth from BioPharma partners in Q3 2026 as recently signed projects continue to generate revenue

Driving operational excellence

• Remained laser-focused on operational excellence and improved adjusted EBITDA loss by 31% year-over-year to $6.1 million
• Reaffirmed commitment to profitable growth and crossing over to positive adjusted EBITDA in the second half of 2027

2026 Financial Outlook

Based on information as of today, SOPHiA GENETICS expects:

• Full year revenue to be at the upper end of its previously issued guidance range of $94 million to $96 million, reflecting strong business performance partially offset by the impact of foreign exchange rate movements at the end of the third quarter, which, if sustained, would be a headwind to fourth-quarter revenue.
• Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025

Earnings Call and Webcast Information

SOPHiA GENETICS will host a conference call and live webcast to discuss the third quarter 2026 results on Tuesday, November 3, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

Non-IFRS Financial Measures

Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-IFRS measure) to loss for the period (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying depreciation expense, amortization of capitalized research & development expenses and intangible assets, interest income, interest expense, fair value adjustments on warrants, income taxes, foreign exchange gains or losses, share-based compensation expenses, social charges on share-based compensation, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs, litigation expenses and restructuring costs that are necessary for such reconciliation.

To provide investors with additional information regarding the company’s financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:

• Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;
• Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;
• Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, social charges on share-based compensation, non-cash pension expenses, certain transaction costs, litigation expenses and restructuring costs.

These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS’ results as reported under IFRS. Some of these limitations are:

• These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company’s financial liabilities;
• These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company’s financial assets;
• These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates;
• These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company’s functional currency;
• These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations;
• These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company’s business and an important part of its compensation strategy;
• These non-IFRS measures exclude the impact of social charges related to share-based compensation. These social charges have been, and will continue to be for the foreseeable future, a recurring expense in the company’s business;
• These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;
• These non-IFRS measures exclude the impact of certain capital markets transaction costs. These costs may occur from time to time in the future as needed to complete the transactions;
• These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health. These expenses are expected to continue for the duration of the litigation and may increase in future periods;
• These non-IFRS measures exclude the costs associated with restructuring, which consists of compensation paid to employees during their garden leave period, severance, and any other amounts legally owed to the employees resulting from their termination as part of a planned workforce reduction, which we undertook to optimize our operations. Additionally, it includes any legal fees incurred as part of the restructuring process. While such actions are not planned going forward as part of our regular operations, we expect such expenses could still be incurred from time to time based on corporate needs;and
• Other companies, including companies in the company’s industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.

Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.

The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.

Presentation of Constant Currency Revenue

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period.

The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.

The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact:
Kellen Sanger
[email protected]

Media Contact:
Sarah Mack
[email protected]

BOSTON, United States and ROLLE, Switzerland, October 20, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2026 before U.S. markets open on Tuesday, November 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the website after its completion.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Investor Contact
Kellen Sanger
[email protected]

Media Contact
Sarah Mack
[email protected]

Dr. Arantxa Hervás, CGT Dx Director at Vitrolife Group, shares how her team modernized carrier screening across a global network processing over 1,300 samples per month, moving toward a more harmonized approach to expanded carrier screening (CGT).

She walks through Vitrolife's partnership with SOPHiA GENETICS and adoption of the SOPHiA DDM™ Enhanced Clinical Exome Solution, which cut turnaround time from 21 to 15 days and reduced complementary testing from 11 assays to 4, while strengthening detection of complex variants and CNVs in line with ACMG standards.

Watch the recording for implementation learnings and the outcomes Vitrolife has achieved since unifying its workflow.

Speaker

SOPHiA DDM™ Enhanced Exome Solutions are for Research Use Only (RUO); RUO results must not be used for clinical diagnosis or patient management.

BOSTON and SALT LAKE CITY - October 8, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. 

Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice® CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. 

“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.” 

As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad’s PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS’ technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. 

“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. “By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.” 

Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer 

Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period. 

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM^TM, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

About Myriad Genetics  
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. 

SOPHiA GENETICS Safe Harbor Statement  

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.  

Investor Contacts 

Kellen Sanger 
[email protected] 

Matt Scalo  
(801) 584-3532  
[email protected]  

Media Contacts 
Sarah Mack 
[email protected] 

Andria Rosell 
(385) 202-3510  
[email protected]   

Most hereditary cancer NGS workflows are built to catch SNVs and indels. But copy number variations (CNVs) can be just as clinically significant, and far easier to miss, particularly in genes like PALB2, where large deletions are more common than many realise.​

What began as a straightforward hereditary cancer study led somewhere no one expected. Dr. Elena Tenedini (Associate Professor at University Hospital of Modena) and colleagues compared variants from nearly 3,000 patients against published cohorts. When they reached the CNV data, PALB2 emerged as a leading contributor of pathogenic CNVs, driven largely by a recurrent exon 11 deletion clustered in one region of Italy. Collaboration with the University of Florence pointed to a shared, relatively recent origin.​

None of this would have surfaced without analysing CNVs and SNVs/indels together. In this on-demand webinar, hosted by Front Line Genomics, Dr. Tenedini shows how her laboratory built a single NGS workflow with the SOPHiA DDM™ Dx Hereditary Cancer Solution, and how integrated analysis uncovers patterns researchers didn't know to look for.​

What you'll learn:​

• How the Modena lab integrates CNV detection with SNV/indel analysis in routine diagnostics​
• What breakpoint and haplotype findings suggest about a regional founder effect, and what it could mean for testing and genetic counselling​
• Where an enhanced exome solution fits within SOPHiA GENETICS' hereditary cancer portfolio for labs consolidating workflows​

Stay for the Q&A​

Dr. Tenedini answers audience questions on founder variants in the clinic, follow-up for families with the PALB2 variant, why CNVs are underreported, and the future of hereditary cancer testing, from long-read sequencing to newer reference genomes.​

Speakers:

Next-generation sequencing (NGS) has transformed the diagnosis and management of haematologic malignancies, providing increasingly detailed insights into the molecular drivers of disease. However, many workflows continue to rely on single time point genomic assessments, limiting opportunities to leverage sequencing data throughout the patient journey.​

In this webcast, Dr Todd Knepper of Moffitt Cancer Center will share lessons from a molecular tumour board and discuss how genomic information can support decision-making beyond initial diagnosis. Drawing on clinical experience and real-world examples, he will explore the role of NGS for risk assessment, monitoring clonal evolution, post-transplant surveillance and the interpretation of complex molecular findings.​

He will also examine the challenges posed by clonal haematopoiesis of indeterminate potential (CHIP) and the importance of multidisciplinary approaches to genomic interpretation. Attendees will gain insight into emerging strategies for identifying and monitoring high-risk cases, and how expanded NGS applications might help to integrate precision oncology more effectively into routine haematology practice.​

Learn:​

• How molecular tumour boards translate complex genomic findings in actionable insights​
• What limits the wider use of NGS in blood cancer patient journeys​
• Which emerging strategies could help to bring precision oncology into routine haematology practice​

Speakers:​

Moderator:

Nikki Forrester​
Freelance Science​ Writer and Editor​

Large hospitals face a widening gap: guidelines are moving faster than most labs can validate against. And legacy PCR- and FISH-based workflows, however reliable, weren't built to scale to that pace. Prof. Klaus Schmetterer, Head of the Molecular Diagnostics Department, and his team at the Medical University of Vienna, Austria, one of Europe's largest tertiary care centers, are closing that gap.

In this session, Prof. Schmetterer shows how his team unlocked roughly 12 times more genomic coverage, at a comparable cost, without slowing down the turnaround clinicians rely on for treatment decisions. The shift: replacing a patchwork of single-gene and translocation assays with one integrated DNA/RNA NGS workflow, covering 500+ genes and 250+ translocations across both myeloid and lymphoid disease in a single run, powered by automated library preparation and the SOPHiA DDM™ platform's AI-driven variant analysis.

At the conclusion of this session, participants will be able to:

• Examine a practical model for scaling genomic testing in hematological malignancies through a single, comprehensive NGS application.
• Compare the operational and financial trade-offs of a consolidated workflow against running multiple fragmented assays, without added budget, headcount, or risk.
• Recognize how structured documentation support can help laboratory teams meet the EU's IVDR requirements while easing the workload that comes with it.

Presenter

Prof. Klaus Schmetterer, MD, PhD, heads the Cytogenetics Diagnostics section and the Molecular Biology in Hemato-Oncology Diagnostics section within the Department of Laboratory Medicine at the Medical University of Vienna (AKH Wien, Austria), roles he holds since 2022 and 2025 respectively. He also holds a tenure-track position at the university since 2021.

His path into hemato-oncology diagnostics began in immunology: he completed his Master's and PhD research in the laboratory of Winfried Pickl, MD, at the Institute of Immunology, Medical University of Vienna, earning his MD in 2010 and his PhD in Molecular Biology in 2011. He joined the Department of Laboratory Medicine in 2012 for his residency and completed it in 2018 as a board-certified specialist in Laboratory Medicine.

BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

• Revenue was $23.3 million, up 27% year-over-year
• Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4% adjusted in the prior year period
• Net loss was $22.4 million, flat year-over-year; Adjusted EBITDA loss was $8.8 million, improving 27% year-over-year
• The company is raising 2026 revenue guidance to a range of $94 million to $96 million, representing 22% to 24% year-over-year growth. This compares to the prior range of $92 million to $94 million

“We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%,” said Ross Muken, Chief Executive Officer of SOPHiA GENETICS. “Strong revenue performance was driven by 60% volume growth in the U.S., 70% volume growth in Liquid Biopsy, and accelerating growth in BioPharma. BioPharma growth is well-positioned to continue into 2027, as today we announce the signing of two companion diagnostic programs with AstraZeneca, the first ever in SOPHiA GENETICS' history."

Muken added, “As I step into the role of CEO, my focus will be on converting our world-class AI platform, a hard-won global network, and a decade of scientific credibility into accelerating, profitable growth for years to come. To achieve these goals, we strengthened our balance sheet with an oversubscribed $57.5 million public offering in Q2, providing sufficient capital to reach our business objectives and invest in long-term growth.”

Business Highlights

Expanding with existing customers

• Performed a record 115,000 analyses on SOPHiA DDM^TM, representing 22% year-over-year volume growth
• Delivered strong analysis volume in North America with 60% year-over-year growth in the U.S.
• Expanded our footprint with existing customers as Net Dollar Retention increased to 117% in Q2 2026, up from 107% in Q2 2025
• Reached 542 core genomics customers as of June 30, 2026, up from 490 customers a year ago

Landing new customers to fuel future growth

• Signed 24 new core genomic customers in Q2 2026, which are expected to begin generating revenue over the next twelve months
• Continued to sign premier healthcare institutions across the globe, including Nova Scotia Health Authority for HemOnc; DB Diagnósticos, Brazil’s leading laboratory-support network, for Rare Disorders; and IPO Lisboa, the main cancer center for southern Portugal, for Hereditary Cancer

Accelerating growth in the U.S. market

• Delivered 64% year-over-year revenue growth in the U.S. in Q2 2026 and 60% volume growth
• Completed new customer go-lives for Geisinger Health System in Pennsylvania for Pharmacogenomics, University of Illinois at Chicago for HemOnc, and NYU Langone Health for Solid Tumors
• Signed a strategic collaboration with Children’s Hospital of Philadelphia (CHOP), the nation’s first pediatric hospital and a global leader in pediatric oncology, to develop and launch a next-generation liquid biopsy application specifically designed for pediatric cancers

Scaling growth with new applications

• Delivered 80% year-over-year revenue growth in Liquid Biopsy in Q2 2026
• Reached a total of 80 customers across 30+ countries signed-to-adopt the Liquid Biopsy application MSK-ACCESS^® powered with SOPHiA DDM^TM, with more than half still yet-to-complete implementation
• Signed major new customers to MSK-ACCESS^® in Q2, including AZ Delta Roeselare, one of the largest hospitals in Belgium; Policlinico Riuniti Hospital at the University of Foggia in Italy; and Sultan Qaboos Cancer Center in Oman
• Signed major new customers to the Solid Tumor application MSK-IMPACT^® powered with SOPHiA DDM^TM, including Lifera Omics in Saudi Arabia; CHU Lyon Sud of Hospices Civils de Lyon in France: and Bioma Genetics in Brazil

Developing partnerships to fuel growth

• Signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) to establish a joint venture combining MSK’s clinical expertise with SOPHiA GENETICS’s AI-native platform to accelerate the next generation of precision oncology
• The envisioned joint venture aims to build an ‘AI Lab of the Future’ with infrastructure to develop and launch new applications, support BioPharma partners, and build new multimodal clinical intelligence tools

Building BioPharma partnerships

• Signed a new, multi-year agreement with AstraZeneca to launch two companion diagnostic (CDx) programs: (1) a decentralized Solid Tumor CDx, and (2) a Hematological Oncology test for patients with blood cancer
• Delivered strong growth from BioPharma partners in Q2 2026 as recently signed projects with AstraZeneca, Kartos, and others begin to generate revenue

Driving operational excellence

• Remained laser-focused on operational excellence and improved adjusted EBITDA loss by 27% year-over-year to $8.8 million
• Executed an oversubscribed public offering that raised approximately $57.5 million in gross proceeds, bringing cash and cash equivalents to $107.7 million at the end of Q2 2026; The company expects it now has sufficient capital resources to fund its growth objectives
• Executed targeted cost actions in Q2, modestly reducing headcount and operating spend as AI-driven productivity improvements enabled us to streamline workflows while maintaining investment in key growth areas
• Reaffirmed commitment to profitable growth and the expectation of approaching adjusted EBITDA breakeven by the end of 2026 and crossing over to positive adjusted EBITDA in the second half of 2027

2026 Financial Outlook

Based on information as of today, SOPHiA GENETICS expects:

• Full year revenue between $94 million and $96 million, representing approximately 22% to 24% year-over-year growth. This compares to the prior range of $92 million to $94 million
• Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025

Earnings Call and Webcast Information

SOPHiA GENETICS will host a conference call and live webcast to discuss the second quarter 2026 results on Tuesday, August 4, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion.

Non-IFRS Financial Measures

Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-IFRS measure) to loss for the period (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying depreciation expense, amortization of capitalized research & development expenses and intangible assets, interest income, interest expense, fair value adjustments on warrants, income taxes, foreign exchange gains or losses, share-based compensation expenses, social charges on share-based compensation, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs, litigation expenses and restructuring costs that are necessary for such reconciliation.

To provide investors with additional information regarding the company’s financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures:

• Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses;
• Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue;
• Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, social charges on share-based compensation, non-cash pension expenses, certain transaction costs, litigation expenses and restructuring costs.

These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS’ results as reported under IFRS. Some of these limitations are:

• These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company’s financial liabilities;
• These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company’s financial assets;
• These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates;
• These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company’s functional currency;
• These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations;
• These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures;
• These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company’s business and an important part of its compensation strategy;
• These non-IFRS measures exclude the impact of social charges related to share-based compensation. These social charges have been, and will continue to be for the foreseeable future, a recurring expense in the company’s business;
• These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business;
• These non-IFRS measures exclude the impact of certain capital markets transaction costs. These costs may occur from time to time in the future as needed to complete the transactions;
• These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health. These expenses are expected to continue for the duration of the litigation and may increase in future periods;
• These non-IFRS measures exclude the costs associated with restructuring, which consists of compensation paid to employees during their garden leave period, severance, and any other amounts legally owed to the employees resulting from their termination as part of a planned workforce reduction, which we undertook to optimize our operations. Additionally, it includes any legal fees incurred as part of the restructuring process. While such actions are not planned going forward as part of our regular operations, we expect such expenses could still be incurred from time to time based on corporate needs;and
• Other companies, including companies in the company’s industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures.

Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results.

The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented.

Presentation of Constant Currency Revenue

SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company’s customers’ geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure “constant currency revenue” (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term “constant currency”, it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the “constant currency impact” for the current period.

The company’s management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results.

The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contact:

Kellen Sanger
[email protected]
[email protected]

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Loss
(Amounts in USD thousands, except per share data)
(Unaudited)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
Revenue	$ 23,310	$ 18,323	$ 44,998	$ 36,102
Cost of revenue	(8,249)	(6,053)	(15,188)	(11,624)
Gross profit	15,061	12,270	29,810	24,478
Research and development costs	(8,731)	(8,493)	(18,191)	(17,611)
Selling and marketing costs	(11,186)	(10,034)	(19,999)	(17,568)
General and administrative costs	(15,202)	(12,301)	(28,961)	(23,901)
Other operating income, net	5	66	5	74
Operating loss	(20,053)	(18,492)	(37,336)	(34,528)
Interest income	231	419	520	869
Interest expense	(1,620)	(559)	(3,287)	(1,218)
Fair value adjustments on warrant obligations	(317)	58	(409)	20
Foreign exchange losses, net	(519)	(3,078)	(835)	(3,677)
Loss before income taxes	(22,278)	(21,652)	(41,347)	(38,534)
Income tax expense	(78)	(762)	(331)	(1,265)
Loss for the period	(22,356)	(22,414)	(41,678)	(39,799)
Attributable to the owners of the parent	(22,356)	(22,414)	(41,678)	(39,799)
Basic and diluted loss per share	$ (0.30)	$ (0.33)	$ (0.58)	$ (0.59)

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Comprehensive Loss
(Amounts in USD thousands)
(Unaudited)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
Loss for the period	$ (22,356)	$ (22,414)	$ (41,678)	$ (39,799)
Other comprehensive (loss) income:
Items that may be reclassified to statement of loss
Currency translation adjustments	(81)	9,016	(611)	11,602
Total items that may be reclassified to statement of loss	(81)	9,016	(611)	11,602
Items that will not be reclassified to statement of loss (net of tax)
Remeasurement of defined benefit plans	317	46	440	93
Total items that will not be reclassified to statement of loss	317	46	440	93
Other comprehensive (loss) income for the period	$ 236	$ 9,062	$ (171)	$ 11,695
Total comprehensive loss for the period	$ (22,120)	$ (13,352)	$ (41,849)	$ (28,104)
Attributable to owners of the parent	$ (22,120)	$ (13,352)	$ (41,849)	$ (28,104)

SOPHiA GENETICS SA
Interim Condensed Consolidated Balance Sheets
(Amounts in USD thousands)
(Unaudited)

	June 30, 2026	December 31, 2025
Assets
Current assets
Cash and cash equivalents	$ 107,665	$ 70,289
Accounts receivable	14,112	15,001
Inventory	7,084	6,351
Prepaids and other current assets	8,429	7,438
Total current assets	137,290	99,079
Non-current assets
Property and equipment	4,903	5,665
Intangible assets	36,163	35,891
Right-of-use assets	11,039	12,382
Deferred tax assets	1,769	1,831
Other non-current assets	7,195	8,183
Total non-current assets	61,069	63,952
Total assets	$ 198,359	$ 163,031
Liabilities and equity
Current liabilities
Accounts payable	$ 11,904	$ 8,960
Accrued expenses	18,699	20,736
Deferred contract revenue	15,616	16,720
Lease liabilities, current portion	2,720	2,700
Warrant obligations	2,144	1,412
Total current liabilities	51,083	50,528
Non-current liabilities
Borrowings	47,999	47,733
Lease liabilities, net of current portion	11,108	12,587
Defined benefit pension liabilities	3,822	4,162
Other non-current liabilities	1,229	876
Total non-current liabilities	64,158	65,358
Total liabilities	115,241	115,886
Equity
Share capital	4,814	4,814
Share premium	542,657	473,675
Treasury shares	(183)	(1,218)
Other reserves	96,784	89,150
Accumulated deficit	(560,954)	(519,276)
Total equity	83,118	47,145
Total liabilities and equity	$ 198,359	$ 163,031

SOPHiA GENETICS SA
Interim Condensed Consolidated Statements of Cash Flows
(Amounts in USD thousands)
(Unaudited)

	Six months ended June 30,
	2026	2025
Operating activities
Loss before tax	$ (41,347)	$ (38,534)
Adjustments for non-monetary items
Depreciation	2,159	1,927
Amortization	3,499	2,740
Finance expense, net	3,354	4,037
Fair value adjustments on warrant obligations	409	(20)
Expected credit loss allowance increase (reversal)	40	252
Share-based compensation	7,805	8,191
Movements in provisions and pensions	440	304
Research tax credit	(441)	(528)
Working capital changes
Decrease (increase) in accounts receivable	589	(1,298)
Decrease (increase) in prepaids and other assets	628	934
Decrease (increase) in inventory	(1,123)	362
Increase (decrease) in accounts payables, accrued expenses, deferred contract revenue, and other liabilities	1,227	2,815
Cash used in operating activities	(22,761)	(18,818)
Income tax paid	(51)	(146)
Net cash flows used in operating activities	(22,812)	(18,964)
Investing activities
Purchase of property and equipment	(1,026)	(130)
Acquisition of intangible assets	—	(87)
Capitalized development costs	(4,541)	(3,250)
Interest received	520	876
Net cash flow used in investing activities	(5,047)	(2,591)
Financing activities
Proceeds from exercise of share options	1,233	115
Interest paid	(2,715)	(1,240)
Proceeds from borrowings, net of transaction costs	—	34,563
Proceeds from sale of common stock in at-the-market offering, net of transaction costs	15,667	—
Proceeds from sale of common stock in follow-on offering, net of transaction costs	54,048	—
Payments of principal portion of lease liabilities	(1,201)	(889)
Net cash flow provided by/(used in) financing activities	67,032	32,549
Increase (decrease) in cash and cash equivalents	39,173	10,994
Effect of exchange differences on cash balances	(1,797)	3,602
Cash and cash equivalents at beginning of the period	70,289	80,226
Cash and cash equivalents at end of the period	$ 107,665	$ 94,822

SOPHiA GENETICS SA
Reconciliation of IFRS Net Loss to Adjusted EBITDA
(Amounts in USD thousands)
(Unaudited)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
IFRS loss for the period	$ (22,356)	$ (22,414)	$ (41,678)	$ (39,799)
Exclude the impact of:
Depreciation	$ 1,080	$ 942	$ 2,159	$ 1,927
Amortization(3)(4)	1,827	1,428	3,499	2,740
Interest income	(231)	(419)	(520)	(869)
Interest expense	1,620	559	3,287	1,218
Fair value adjustments on warrant obligations	317	(58)	409	(20)
Foreign exchange losses, net	519	3,078	835	3,677
Income tax expense	78	762	331	1,265
Share-based compensation expense(1)	4,492	4,356	7,805	8,191
Social charges related to share-based compensation(7)	1,240	(360)	2,308	(5)
Non-cash pension expense(2)	72	89	163	175
Transaction costs(5)	123	—	291	—
Litigation expenses(6)	1,130	—	1,819	—
Restructuring costs(8)	1,255	—	1,255	—
Adjusted EBITDA	$ (8,834)	$ (12,037)	$ (18,037)	$ (21,500)

SOPHiA GENETICS SA
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
(Amounts in USD thousands, except for %)
(Unaudited)

	Three months ended June 30,			Six months ended June 30,
	2026	2025	Growth	2026	2025	Growth
IFRS revenue	$ 23,310	$ 18,323	27%	$ 44,998	$ 36,102	25%
Current period constant currency impact	(454)	—		(1,936)	—
Constant currency revenue	$ 22,856	$ 18,323	25%	$ 43,062	$ 36,102	19%

SOPHiA GENETICS SA
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
(Amounts in USD thousands, except percentages)
(Unaudited)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
Revenue	$ 23,310	$ 18,323	$ 44,998	$ 36,102
Cost of revenue	(8,249)	(6,053)	(15,188)	(11,624)
Gross profit	$ 15,061	$ 12,270	$ 29,810	$ 24,478
Amortization of capitalized research and development expenses(3)	1,757	1,357	3,359	2,598
Adjusted gross profit	$ 16,818	$ 13,627	$ 33,169	$ 27,076
Gross profit margin	64.6%	67.0%	66.2%	67.8%
Amortization of capitalized research and development expenses(3)	7.5%	7.4%	7.5%	7.2%
Adjusted gross profit margin	72.1%	74.4%	73.7%	75.0%

BOSTON and ROLLE – August 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS’s decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.

As part of the collaboration, SOPHiA GENETICS will develop its Solid Tumor application into a decentralized companion diagnostic. In addition, the company will develop and validate its Hematological Oncology application to support a companion diagnostic program for patients with blood cancer.

“A breakthrough therapy only matters to the patients we can find in time to treat. We are moving towards a future that no longer depends on geography, where any laboratory can run the same test to the same high standard on day one of a launch. We believe these programs are what that future looks like in practice. Bringing the right therapy to the right patient, in any country and any laboratory, is the work that will define the next generation of precision medicine,” said Ross Muken, CEO, SOPHiA GENETICS.

By combining accurate biomarker detection with rapid deployment, SOPHiA GENETICS aims to shorten the distance between a new therapy and the patients who need it. Through its global data-driven platform, insights generated from patient populations can help advance informed clinical decision-making across healthcare systems. This vision of connected, data-driven medicine underpins these programs, with the goal of expanding access to innovative treatments and improving outcomes for patients worldwide.

About SOPHiA GENETICS Companion Diagnostics

SOPHiA GENETICS end-to-end diagnostic capabilities span the drug development and launch continuum:

• Clinical Trial Assay (CTA) development, to identify, screen, and enroll the right patients quickly and accurately during a trial.
• Companion Diagnostic (CDx) development, validation, and regulatory submission, taking an assay from research use through analytical and clinical validation to approval in the US, EU, Japan, and beyond.
• Deployment through the SOPHiA DDM™ Platform and the SOPHiA DDM^TM MaxCare Program, enabling laboratories to bring testing in-house and adopt new genomic applications with confidence, reaching larger populations around the globe.

SOPHiA GENETICS’s technology-agnostic, cloud-based platform lets healthcare institutions run the same validated, AI-powered analysis locally, while sharing and benefiting from the collective intelligence of a global network of more than 1,000 connected institutions across over 75 countries. For a pharmaceutical partner preparing a global launch, that means a companion diagnostic that can be available in the local lab on day one of drug approval.

About SOPHiA GENETICS  

SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:  

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

Media and Investor Contact
Kellen Sanger
[email protected]
[email protected]